B. Metzler seel. Sohn & Co. Holding AG Invests $830,000 in Axsome Therapeutics, Inc. (NASDAQ:AXSM)

B. Metzler seel. Sohn & Co. Holding AG acquired a new position in shares of Axsome Therapeutics, Inc. (NASDAQ:AXSM) during the third quarter, HoldingsChannel reports. The firm acquired 9,241 shares of the company’s stock, valued at approximately $830,000.

Several other institutional investors have also added to or reduced their stakes in AXSM. Whalen Wealth Management Inc. acquired a new stake in shares of Axsome Therapeutics in the 3rd quarter valued at about $236,000. Royce & Associates LP grew its holdings in shares of Axsome Therapeutics by 73.1% during the third quarter. Royce & Associates LP now owns 22,500 shares of the company’s stock worth $2,022,000 after buying an additional 9,500 shares in the last quarter. WCM Investment Management LLC raised its position in Axsome Therapeutics by 0.3% in the 3rd quarter. WCM Investment Management LLC now owns 113,692 shares of the company’s stock valued at $10,191,000 after buying an additional 347 shares during the last quarter. Versor Investments LP bought a new stake in Axsome Therapeutics in the 3rd quarter valued at approximately $791,000. Finally, Privium Fund Management B.V. boosted its position in Axsome Therapeutics by 7.9% during the 3rd quarter. Privium Fund Management B.V. now owns 80,232 shares of the company’s stock worth $7,210,000 after acquiring an additional 5,900 shares during the last quarter. 81.49% of the stock is owned by institutional investors.

Axsome Therapeutics Price Performance

Shares of Axsome Therapeutics stock opened at $98.68 on Friday. The company has a quick ratio of 2.37, a current ratio of 2.44 and a debt-to-equity ratio of 1.97. The stock has a market capitalization of $4.78 billion, a price-to-earnings ratio of -15.11 and a beta of 1.26. Axsome Therapeutics, Inc. has a twelve month low of $60.28 and a twelve month high of $105.00. The company has a 50-day simple moving average of $90.99 and a two-hundred day simple moving average of $85.01.

Axsome Therapeutics (NASDAQ:AXSM) last issued its quarterly earnings results on Tuesday, November 12th. The company reported ($1.34) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.38) by $0.04. Axsome Therapeutics had a negative return on equity of 158.36% and a negative net margin of 91.87%. The business had revenue of $104.76 million during the quarter, compared to analysts’ expectations of $98.71 million. During the same period in the previous year, the company posted ($1.32) earnings per share. Analysts forecast that Axsome Therapeutics, Inc. will post -4.75 EPS for the current year.

Analysts Set New Price Targets

A number of brokerages have recently commented on AXSM. HC Wainwright reissued a “buy” rating and issued a $180.00 price objective on shares of Axsome Therapeutics in a research report on Thursday, September 5th. Cantor Fitzgerald reissued an “overweight” rating and set a $107.00 price target on shares of Axsome Therapeutics in a research report on Monday, September 16th. Royal Bank of Canada raised their price objective on Axsome Therapeutics from $130.00 to $131.00 and gave the company an “outperform” rating in a report on Friday, October 4th. StockNews.com upgraded Axsome Therapeutics from a “sell” rating to a “hold” rating in a report on Wednesday. Finally, Needham & Company LLC restated a “buy” rating and issued a $130.00 price target on shares of Axsome Therapeutics in a research note on Tuesday, November 12th. One analyst has rated the stock with a hold rating and fourteen have given a buy rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $124.93.

Insider Activity

In other Axsome Therapeutics news, Director Mark E. Saad sold 11,016 shares of the firm’s stock in a transaction dated Wednesday, September 11th. The shares were sold at an average price of $91.31, for a total value of $1,005,870.96. Following the transaction, the director now directly owns 10,002 shares of the company’s stock, valued at $913,282.62. This trade represents a 52.41 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Corporate insiders own 22.40% of the company’s stock.

Axsome Therapeutics Company Profile

Axsome Therapeutics, Inc, a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company’s commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea.